A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
Public ClinicalTrials.gov record NCT05462756. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.
Study identification
- NCT ID
- NCT05462756
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 730 participants
Conditions and interventions
Interventions
- Insulin Efsitora Alfa Drug
- Insulin Lispro (U100) Drug
- Insulin Glargine (U100) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2022 (Actual)
- Primary completion
- Feb 27, 2024 (Actual)
- Completion
- Feb 27, 2024 (Actual)
- Last update posted
- Apr 27, 2025
2022 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CMR of Greater New Haven, LLC | Hamden | Connecticut | 06517 | — |
| Tampa Bay Medical Research | Clearwater | Florida | 33761 | — |
| Panax Clinical Research | Miami Lakes | Florida | 33014 | — |
| Encore Medical Research - Weston | Weston | Florida | 33331 | — |
| Elite Clinical Trials | Blackfoot | Idaho | 83221 | — |
| Rocky Mountain Clinical Research | Idaho Falls | Idaho | 83404 | — |
| MedStar Good Samaritan Hospital | Baltimore | Maryland | 21239 | — |
| NECCR PrimaCare Research | Fall River | Massachusetts | 02721 | — |
| Arcturus Healthcare , PLC, Troy Internal Medicine Research Division | Troy | Michigan | 48098 | — |
| Palm Research Center Tenaya | Las Vegas | Nevada | 89128 | — |
| Palm Research Center Sunset | Las Vegas | Nevada | 89148 | — |
| Research Foundation of SUNY - University of Buffalo | Buffalo | New York | 14221 | — |
| Remington Davis Clinical Research | Columbus | Ohio | 43215 | — |
| Aventiv Research | Dublin | Ohio | 43016 | — |
| Heritage Valley Multispecialty Group, Inc | Beaver | Pennsylvania | 15009 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Texas Diabetes & Endocrinology, P.A. | Austin | Texas | 78731 | — |
| Texas Diabetes & Endocrinology, P.A. | Austin | Texas | 78749 | — |
| North Texas Endocrine Center | Dallas | Texas | 75231 | — |
| Biopharma Informatic, LLC | Houston | Texas | 77043 | — |
| Research Institute of Dallas | Plano | Texas | 75093 | — |
| Consano Clinical Research, LLC | Shavano Park | Texas | 78231 | — |
| Chrysalis Clinical Research | St. George | Utah | 84790 | — |
| Rainier Clinical Research Center | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05462756, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05462756 live on ClinicalTrials.gov.